When Does Maintenance Efficacy End and Withdrawal Relapse Begin? Interpreting the QUASAR East Asian Subgroup Data
Journal of Gastroenterology and Hepatology · 2026-06 · 41 (6) · 1940-1941
DOI: 10.1111/jgh.70418 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of Gastroenterology and Hepatology, online erschienen am 06.05.2026. Verfasst von Huan Deng und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesia, the Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen, China. Die Arbeit nennt 6 Literaturangaben. Gefördert von: General Project of Public Health Research in Shenzhen Futian District.
Abstract (Originalsprache)
The recent subgroup analysis of the QUASAR program evaluating guselkumab in East Asian patients with moderate- to-severe ulcerative colitis provides valuable efficacy and safety data in this understudied population [1]. We offer a brief methodological note on the interpretation of the maintenance phase results. The QUASAR maintenance study used a standard randomized withdrawal design: All placebo-assigned participants had responded to intravenous guselkumab induction before being rerandomized to subcutaneous placebo. Although this design is methodologically sound [2], it complicates distinguishing the sustained benefit of continued guselkumab from disease relapse following treatment withdrawal. In the East Asian subgroup, Week 44 clinical remission was 46.3% with subcutaneous guselkumab 200 mg every 4 weeks, compared with 13.3% in the placebo withdrawal arm [3]. This large difference likely reflects both the durable efficacy of continued guselkumab and the inherent relapse risk following induction therapy withdrawal. Similar withdrawal-related relapse has been well documented in ulcerative colitis [4]. For example, azathioprine withdrawal increases 1-year relapse risk by approximately 23 percentage points, and ozanimod withdrawal results in a similar rise in relapse at Week 42. These observations confirm that treatment withdrawal substantially contributes to efficacy differences in maintenance trials [5]. The East Asian QUASAR data strongly support continued guselkumab
Autor:innen und Institutionen
- Department of Anesthesia, the Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen, China.
ORCID-Profile: Yue Peng
Förderung
- General Project of Public Health Research in Shenzhen Futian District
Zitieren
APA
Deng, H., & Peng, Y. (2026). When Does Maintenance Efficacy End and Withdrawal Relapse Begin? Interpreting the QUASAR East Asian Subgroup Data. Journal of Gastroenterology and Hepatology, 41(6), 1940-1941. https://doi.org/10.1111/jgh.70418
Vancouver
Deng H, Peng Y. When Does Maintenance Efficacy End and Withdrawal Relapse Begin? Interpreting the QUASAR East Asian Subgroup Data. Journal of Gastroenterology and Hepatology. 2026;41(6):1940-1941. doi:10.1111/jgh.70418
BibTeX
@article{Deng2026,
author = {Deng, Huan and Peng, Yue},
title = {When Does Maintenance Efficacy End and Withdrawal Relapse Begin? Interpreting the QUASAR East Asian Subgroup Data},
journal = {Journal of Gastroenterology and Hepatology},
year = {2026},
volume = {41},
number = {6},
pages = {1940--1941},
doi = {10.1111/jgh.70418}
}
EUVIMED